- Home
- GMAB vs RPRX Comparison
GMAB vs RPRX Comparison
Compare GMAB & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- RPRX
- Stock Information
- Founded
- GMAB 1999
- RPRX 1996
- Country
- GMAB Denmark
- RPRX United States
- Employees
- GMAB 2638
- RPRX N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- GMAB Health Care
- RPRX Health Care
- Exchange
- GMAB Nasdaq
- RPRX Nasdaq
- Market Cap
- GMAB 13.4B
- RPRX 13.9B
- IPO Year
- GMAB N/A
- RPRX 2020
- Fundamental
- Price
- GMAB $22.25
- RPRX $33.39
- Analyst Decision
- GMAB Buy
- RPRX Strong Buy
- Analyst Count
- GMAB 9
- RPRX 3
- Target Price
- GMAB $39.17
- RPRX $47.33
- AVG Volume (30 Days)
- GMAB 1.3M
- RPRX 5.6M
- Earning Date
- GMAB 05-08-2025
- RPRX 05-08-2025
- Dividend Yield
- GMAB N/A
- RPRX 2.62%
- EPS Growth
- GMAB 276.80
- RPRX 37.60
- EPS
- GMAB 18.36
- RPRX 2.45
- Revenue
- GMAB $3,230,902,140.00
- RPRX $2,263,845,000.00
- Revenue This Year
- GMAB $747.74
- RPRX $29.35
- Revenue Next Year
- GMAB $14.81
- RPRX $7.58
- P/E Ratio
- GMAB $1.21
- RPRX $13.72
- Revenue Growth
- GMAB 25.43
- RPRX 1.13
- 52 Week Low
- GMAB $17.24
- RPRX $24.05
- 52 Week High
- GMAB $28.56
- RPRX $34.32
- Technical
- Relative Strength Index (RSI)
- GMAB 64.68
- RPRX 54.66
- Support Level
- GMAB $20.88
- RPRX $32.29
- Resistance Level
- GMAB $22.15
- RPRX $33.97
- Average True Range (ATR)
- GMAB 0.39
- RPRX 0.57
- MACD
- GMAB 0.14
- RPRX 0.05
- Stochastic Oscillator
- GMAB 94.62
- RPRX 68.13
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.